BML-190

BML-190
Clinical data
Other names	BML190; Indomethacin morpholinylamide
ATC code	None;
Identifiers
	IUPAC name 2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]-1-morpholin-4-ylethanone;
CAS Number	2854-32-2 ;
PubChem CID	2415;
ChemSpider	2321 ;
CompTox Dashboard (EPA)	DTXSID50951230 ;
Chemical and physical data
Formula	C23H23ClN2O4
Molar mass	426.90 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C4COCCN4C(=O)Cc(c(c1cc2)cc2OC)c(C)n1C(=O)c3ccc(Cl)cc3;
	InChI InChI=1S/C23H23ClN2O4/c1-15-19(14-22(27)25-9-11-30-12-10-25)20-13-18(29-2)7-8-21(20)26(15)23(28)16-3-5-17(24)6-4-16/h3-8,13H,9-12,14H2,1-2H3 ; Key:BJSDNVVWJYDOLK-UHFFFAOYSA-N ;
	(what is this?) (verify)

BML-190, also known as indomethacin morpholinylamide, is a drug used in scientific research that acts as a selective CB₂ inverse agonist.^[1] BML-190 is structurally derived from the NSAID indomethacin but has a quite different biological activity.^[2] The activity produced by this compound is disputed, with some sources referring to it as a CB₂ agonist rather than an inverse agonist;^[3]^[4] this may reflect an error in classification, or alternatively it may produce different effects in different tissues, and more research is required to resolve this dispute.